Sanofi Hits M&A Trail Again To Buy UK's KyMab
Gets Hold Of Gets Mid-Stage Atopic Dermatitis Drug
Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.
You may also be interested in...
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.
Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.